<img height="1" width="1" style="display:none;" alt="" src="https://px.ads.linkedin.com/collect/?pid=1400074&amp;fmt=gif">

Video & Presentation library

Browse our video and presentation library to learn more about our tests and how we're helping improve lung cancer treatment options.

Blood-based Biomarkers for Evaluation of Pulmonary Nodules

In this CHEST Webinar, Gerard Silvestri, MD discusses how blood-based biomarkers can help address challenges in nodule management. Dr. Silvestri was the lead author of the clinical validation study (PANOPTIC) for the Nodify XL2 blood-based lung nodule test.

Presented Online May 18, 2020

Nodify LungTM Nodule Risk Assessment

Nodify Lung testing reclassifies an estimated 35% of patients with low to moderate risk nodules into the very low or high risk groups so that physicians can identify lung cancer quickly and reduce unnecessary invasive procedures on benign nodules.

Presented Online May 13, 2020

How the Nodify XL2 Test Helps Identify Benign Lung Nodules is Relieving Patient Anxiety

Dr. Susan Garwood, M.D., Pulmonary and Advanced Bronchoscopy Lung Cancer Specialist with Centennial Medical Center in Nashville, part of the HCA TriStar division and Tresia Michael, LPN, Lung Nodule Coordinator for TriStar Health discuss how the Nodify XL2 test is relieving patient anxiety in their lung nodule clinic.

Presented Online on December 13, 2019

How Lung Nodule Clinics Use a Blood-Based Test to Help Identify Benign Lung Nodules

Dr. Susan Garwood, M.D., Pulmonary and Advanced Bronchoscopy Lung Cancer Specialist with Centennial Medical Center in Nashville, part of the HCA TriStar division and Tresia Michael, LPN, Lung Nodule Coordinator for Tri-Star Health discuss how they use the Nodify XL2 test in their clinic.

Presented Online on December 13, 2019

Three Physicians Give Insight into How Nodfiy XL2 Testing is Relieving Patient Stress and Helping Avoid Unnecessary Procedures

Three leading pulmonologists, Dr. Michael Pritchett, Dr. Krish Bhadra, and Dr. Mark Bowling provide insight into how the Nodify XL2™ test is helping relieve patient stress and how it may reduce invasive procedures on benign lung nodules by 40%. 

Presented Online December 12, 2019

Dr. Susan Garwood from TriStar Centennial Medical Center discusses lung nodule management

Nodify XL2™ is an easy outpatient blood-based test that answers a complex clinical problem. In just five days, this test has the potential to reduce unnecessary procedures in benign nodules by 40%. And at the heart of it all is a patient who will have the confidence to know that their physician now has a clear path forward.

Presented Online on November 4, 2019

A Look at the Future of Blood-Based Companion Diagnostics

Three leading experts in liquid biopsy diagnostic development, Gary Pestano, Viresh Patel and Dawne Shelton bring you insight into the developmental blueprint for blood-based IVDs. Novel case study data on the development of blood-based MSI, ALK, ROS and RET assays are discussed.

Presented Online on August 8, 2018

Applied Machine Learning in the Development of Immuno-Oncology Diagnostics

Dr. Mario Sznol presented on the complexity of the IO monotherapy and combination therapy clinical landscape and how a new era of proteomic based diagnostics will overcome unmet clinical needs. Dr. Heinrich Roder followed this by discussing how machine learning can be harnessed to design diagnostic classifiers, detailing how platforms infused with these capabilities can be taken forward as companion diagnostics.

Presented Online on November 15, 2017

Pre-Analytical Variable Considerations in the Development of Robust DNA and RNA ddPCR Assays

Learn how Streck blood collection tubes can help preserve valuable samples for liquid biopsy assay development. Hestia Mellert, PhD, Director of Molecular Product Development at Biodesix, describes pre-analytical considerations with the GeneStrat® genomic test.

Presented April 4, 2017 at American Association for Cancer Research (AACR) Annual Meeting in Washington, D.C.

Victoria’s Story (A Patient's Experience with Biodesix Lung Reflex testing)

Victoria Bannister discovered that she had lung cancer during an unrelated doctor visit in early 2016. While seeking treatment she became frustrated with the long turnaround time on traditional tissue biopsy results. With the blood-based Biodesix Lung Reflex testing strategy, Victoria received her genomic and proteomic results in 72 hours and was able to quickly initiate treatment with a targeted therapy.

Specimen collection videos

View Specimen Collection Videos

Contact our team to learn more

Contact us